Joshua T. Brumm - 08 Dec 2025 Form 4 Insider Report for CRESCENT BIOPHARMA, INC. (GLYC)

Role
Chief Executive Officer, Director
Signature
/s/ Barbara Bispham, as attorney-in-fact for Joshua T. Brumm
Issuer symbol
GLYC
Transactions as of
08 Dec 2025
Net transactions value
$0
Form type
4
Filing time
10 Dec 2025, 16:35:41 UTC
Previous filing
23 Jun 2025
Next filing
17 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Brumm Joshua T Chief Executive Officer, Director C/O CRESCENT BIOPHARMA, INC., 300 FIFTH AVENUE, WALTHAM /s/ Barbara Bispham, as attorney-in-fact for Joshua T. Brumm 10 Dec 2025 0001528826

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBIO Stock Option (Right to Buy) Award $0 +345,672 $0.000000 345,672 08 Dec 2025 Ordinary Shares 345,672 $13.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase shares of the Issuer's ordinary shares and vests in 48 approximately equal monthly installments that commenced on December 8, 2025.